Summary
AbbVie Inc. (ABBV) filed an 8-K on May 11, 2020, reporting on the results of its Annual Meeting of Stockholders held on May 8, 2020. The primary focus of this filing is to provide the voting outcomes on various proposals presented to shareholders. Notably, all incumbent Class II Directors were re-elected, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2020 was overwhelmingly ratified. Shareholder approval was also obtained for the advisory vote on executive compensation. However, the meeting also saw the rejection of several management and shareholder proposals. A management proposal to eliminate supermajority voting requirements did not pass. Additionally, three shareholder proposals concerning lobbying reports, requiring an independent chair, and issuing a Compensation Committee report on drug pricing were also not approved by the stockholders. These results indicate a mixed reception to proposed governance changes and shareholder initiatives.
Key Highlights
- 1AbbVie Inc. held its Annual Meeting of Stockholders on May 8, 2020.
- 2All Class II Directors up for election were re-elected by a significant margin.
- 3The appointment of Ernst & Young LLP as the independent auditor for 2020 was ratified with strong shareholder support.
- 4Shareholders provided advisory approval for the compensation of named executive officers.
- 5A management proposal to eliminate supermajority voting requirements was not approved by stockholders.
- 6Three shareholder-initiated proposals regarding lobbying reports, independent board chair, and drug pricing compensation reports were also not approved.